| University of South Florida Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136447 | PROSTHESES FOR SPINE DISCS HAVING FUSION CAPABILITY - The present invention provides both a device and a method. The device is a human made replacement for the soft discs in the spine. A fabric pouch encloses a central hydraulic element made up of small soft beads. Two pouches with beads are implanted into a prepared disc space to function as an intervertebral disc. The method is conversion of the device into a fusion element. | 05-31-2012 |
| 20120130384 | Apparatus for Osteotomy and Graft Preparation - Surgical tools that increase surgical accuracy for orthopedic procedures involving long bone osteotomy with or without supplementation with allograft or autograft. Two clamps on the operative side are rigidly interconnected to one another with an adjustable rod that is locked into place, preserving length and rotation of the bone. A graft preparation device is used on the operative table. It enables alignment of the graft to preserve the desired mechanical and anatomic axes and to provide rigid fixation of the graft for cutting. Adjustable jigs ensure exact cuts. | 05-24-2012 |
| 20120128551 | IONIC LIQUID MEDIATED SOL-GEL SORBENTS - Ionic liquid (IL)-mediated sol-gel hybrid organic-inorganic materials present enormous potential for effective use in analytical microextraction. One obstacle to materializing this prospect arises from high viscosity of ILs significantly slowing down sol-gel reactions. A method was developed which provides phosphonium-based, pyridinium-based, and imidazolium-based IL-mediated advanced sol-gel organic-inorganic hybrid materials for capillary microextraction. Scanning electron microscopy results demonstrate that ILs can serve as porogenic agents in sol-gel reactions. IL-mediated sol-gel coatings prepared with silanol-terminated polymers provided up to 28 times higher extractions compared to analogous sol-gel coatings prepared without any IL in the sol solution. This study shows that IL-generated porous morphology alone is not enough to provide effective extraction media: careful choice of the organic polymer and the precursor with close sol-gel reactivity must be made to ensure effective chemical bonding of the organic polymer to the created sol-gel material to be able to provide the desired sorbent characteristics. | 05-24-2012 |
| 20120122700 | MATERIALS AND METHODS FOR DETERMINING SUBTELOMERE DNA SEQUENCE - The subject invention pertains to methods for rapid and accurate determination of subtelomere DNA sequences. Also provided are kits for determination of subtelomere sequences and uses of chromosomal terminal sequences for studying pathogenesis and treatment of diseases. | 05-17-2012 |
| 20120121531 | BIOCOMPOSITE FOR ARTIFICIAL TISSUE DESIGN - The present invention concerns a biocomposite useful in artificial tissue replacement, methods for its production, and methods of use. The biocomposite can be implanted into humans or animals as an artificial tissue for treatment of a tissue defect. The biocomposite can be formed or manipulated into a desired shape for implantation. | 05-17-2012 |
| 20120115904 | COMPOUNDS HAVING ANTIPARASITIC OR ANTI-INFECTIOUS ACTIVITY - Compounds of formula I: | 05-10-2012 |
| 20120093781 | HUMAN MAST CELL LINE AND USES THEREOF - The subject invention pertains to the development of a novel human mast cell line, USF-MC1. USF-MC1 is a mast cell precursor present in human umbilical cord blood (HUCB) that may be sustained in culture in the absence of exogenous cytokines to serve as a convenient experimental model of human mast cell activation. The SCF-independent human mast cell line USF-MC1 responds to IgE-mediated and IgE-independent stimuli in a way comparable to that of LAD2. USF-MC1 cells are useful for investigation of IgE-mediated activation mechanisms of human mast cells, contributing to the development of effective treatments for allergic disorders and other disorders. The subject invention provides a ready source of human mast cells for research, including pharmacological studies for the screening of various agents, and toxicologic, e.g., for the cosmetic and pharmaceutical industries. The mast cells can also be used as biofactories, for the large-scale production of biomolecules. | 04-19-2012 |
| 20120077869 | METHOD AND COMPOSITION USING A DUAL SPECIFICITY PROTEIN TYROSINE PHOSPHATASE AS AN ANTIMALARIAL DRUG TARGET - Phosphotyrosine phosphatase (PTP) encoded by PF13_0027 is a desirable drug target for the human malaria parasite | 03-29-2012 |
| 20120067529 | SHAPE-SHIFTING SURFACES - Shape-shifting surfaces that retain their effectiveness as physical barriers while undergoing changes in shape. The shape changes include any motion that makes the surface more effective at performing its function, such as expansion, shrinkage, twisting, encircling, wiggling, swallowing or constricting. The shape-shifting surfaces include tiled arrays of polygonal cells, each cell including specifically-designed compliant flexures attached to specifically-shaped overlapping thin plates or shells. Applications for such surfaces include micro-scale cellular engineering and macro-scale biomedical applications, recreational uses, national security, and environmental protection. | 03-22-2012 |
| 20120065456 | PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE THROUGH ELECTROMAGNETIC FIELD EXPOSURE - The invention includes a method of treating and preventing a neurological disorder, such as Alzheimer's Disease, in a subject in need thereof by positioning an electromagnetic field emitting source proximal to the subject and exposing the subject to an electromagnetic field having a predetermined frequency for a predetermined absorption period. Preferably, each individual treatment (comprising exposure to the predetermined frequency for the predetermined absorption period) is continued at a predetermined schedule (preferably daily) for a predetermined treatment period. | 03-15-2012 |
| 20120058109 | REELIN RESCUES COGNITIVE FUNCTION - Disclosed are methods of influencing, and enhancing, cognitive function by increasing, and/or preventing interference with, Reelin levels as well as Reelin signaling. Cognitive function is improved, in a subject in need thereof, by administering a therapeutically effective amount of Reelin, a Reelin-specific modulator or an agonist of a lipoprotein receptor to the subject. The lipoprotein receptor can be selected from candidates such as ApoER2 and VLDLR. As disclosed herein, agonists of the lipoprotein receptor for use with the inventive method include APC, Sep and Fc-RAP. In addition to administering exogenous Reelin, a Reelin-specific modulator, such as a recombinant Reelin fragment, can be used to increase Reelin levels and/or signaling. | 03-08-2012 |
| 20120039854 | Nanoparticle Targeted Drug Delivery to the Lungs Using Extra-Testicular Sertoli Cells - A method of delivering a compound of interest to the lungs of a subject by the intravenous injection of Sertoli cells loaded with a plurality of chitosan nanoparticles coupled with the compound of interest is provided. Testis-derived rat Sertoli cells were pre-loaded with chitosan nanoparticles coupled with or without the drug curcumin, pre-labeled with a fluorescent cell marker and then injected intravenously into the control or asthmatic mouse model host. Intact pre-loaded, pre-labeled Sertoli cells were present in the lungs at 15 minutes post-injection, appeared entrapped in the pulmonary pre-capillary vascular bed around alveolar sacs but were not present one hour post-injection although Sertoli cell label and cellular debris was. Most of the of the injected nanoparticle to load (70%) and curcumin load (80%) was present in the lungs 15 minutes post-injection, and remained at 70% and 80%, respectively, one hour post-injection. | 02-16-2012 |
| 20120034614 | EARLY DETECTION OF PATHOGENS IN BLOOD - The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na | 02-09-2012 |
| 20120034186 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND METHOD OF TREATING CANCER - Protein tyrosine phosphatase (PTP) Shp2 is a non-receptor PTP that involved in cell signaling and regulation of cell proliferation, differentiation, and migration. Shp2 mediates activation of kinases that are involved in the pathogenesis of human carcinoma. A high throughput screen identified compounds that inhibit the PTP Shp2. Several compounds were identified that selectively inhibit Shp2 over Shp1 with low to sub-micromolar activity. Also disclosed are methods of inhibiting a protein tyrosine phosphatase in a cell and treating cancer through selective inhibition of Shp2. | 02-09-2012 |
| 20120029067 | Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use - The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers. | 02-02-2012 |
| 20120024790 | SEPARATION COLUMN WITH GERMANIA-BASED SOL-GEL STATIONARY PHASE - The present invention provides sol-gel germania-coated chromatography separation columns with improved stability under extreme pHs and high temperatures. Also provided are methods of preparation and uses of the sol-gel germania-coated separation columns of the present invention. | 02-02-2012 |
| 20120022007 | METHOD AND COMPOSITION FOR MODULATING CANONICAL WNT PATHWAY USING FOLATE AND INOSITOL - The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid, FA) deficiency, the mood-stabilizing drug lithium (Li), and alcohol (ethanol) are linked to the induction of human congenital heart and neural tube defects. FA supplementation ameliorates the observed developmental errors in the Li-HCy, or alcohol-exposed mouse embryos and normalized heart function. Li, HCy or Wnt3A suppress Wnt-modulated Hex and Islet-1 expression. FA protects from the gene misexpression that is induced by all three factors. Administration of myo-inositol with FA synergistically enhances the protective effect. | 01-26-2012 |
| 20120015993 | Novel Pharmaceutical Forms, and Methods of Making and Using the Same - Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided. | 01-19-2012 |
| 20120009271 | METHOD OF DISEASE-INDUCED AND RECEPTOR-MEDIATED STEM CELL NEUROPROTECTION - Stem cells are exposed to disease condition (the OGD stroke model), that mimics the target disease (stroke), allowing the stem cells to exert better neuroprotective effects. Thus, the present technology demonstrates a disease-tailored stem cell therapy. The present invention discloses that the administration of a therapeutically effective amount of amnion derived stem cells concomitantly with a therapeutically effective dose of melatonin provides additive/synergistic neuroprotective effects. Moreover, the present invention offers an equally robust technology employing a receptor-regulated mechanism, whereby stem cells can be enhanced (melatonin treatment) over their basal level (lack of melatonin treatment), facilitating a regulation of stem cells. | 01-12-2012 |
| 20120006314 | SUSTAINED MODULATION OF TEMPERATURE OF SELF HEATING CHEMICAL SYSTEM - Exothermic reactions are used in self heating products, such as food, beverages, and clothing. Temperature peaks are important as heat can cause user injuries or increase pressures within the heating container to unsafe levels. Disclosed is a composition that modulates chemical reactions by control of the reaction initiation. Solid exothermic reactants, like calcium oxide and zeolite, are wetted with a combination of water and at least one surfactant, such as polyethylene glycol. The use of surfactants limits the initial rate of wetting, and also provides modulation of the reaction by changing phase. Optional addition of weak acids or acid salts modulated temperature and pH. | 01-12-2012 |
| 20120004434 | GERMANIA-SILICA-BASED SOL-GEL MONOLITH AND USES THEREOF - The present invention provides germania-silica-based sol-gel monoliths that form the solid-phase material for extraction, isolation, preconcentration, and separation of analytes. In one embodiment, the germania-silica-based sol-gel monolith can be used to coat surfaces of the inner walls of extraction and chromatographic columns. In a preferred embodiment, the sol-gel germania-silica monolith of the present invention is formed from hydrolysis and polycondensation of precursors comprising tetraethoxygermane, tetramethoxysilane, and polyethylene glycol. Also provided are methods of preparing the germania-silica-based sol-gel monolith of the present invention. | 01-05-2012 |
| 20120004169 | MATERIALS AND METHODS FOR TREATMENT OF CANCER AND IDENTIFICATION OF ANTI-CANCER COMPOUNDS - The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity. | 01-05-2012 |
| 20120001094 | DEEP-UV LED AND LASER INDUCED FLUORESCENCE DETECTION AND MONITORING OF TRACE ORGANICS IN POTABLE LIQUIDS - An apparatus for measuring fluorescence of potable liquids contained within an optical quartz cell includes a deep UV laser or a compact UV LED that generates a light beam. A UV blocking and visible light transmitting optical filter reduces out-of-band emission from the LED. The optical quartz cell is between a pair of plane mirrors so that light from the light source travels through it several times. A concave mirror collects a fluorescence signal and has a common optical axis with a lens. The common optical axis is normal to an optical axis of the light beam. The concave mirror and lenses are positioned on opposite sides of the optical quartz cell. A fluorescence detector is in optical alignment with the concave mirror and the lens. A boxcar averager is in electrical communication with the fluorescence detector. Optical wavelength selection of the fluorescence emission uses optical filters or a spectrometer. | 01-05-2012 |
| 20120000850 | SOL-GEL MONOLITHIC COLUMN WITH OPTICAL WINDOW AND METHOD OF MAKING - A method of preparing a sol-gel monolithic column includes the step of forming a separation bed ( | 01-05-2012 |
| 20110318763 | DETECTION OF CANCER BY ELEVATED LEVELS OF BCL-2 - The present invention relates to a method for the diagnosis, prognosis, and monitoring of cancer, such as early or late stage ovarian cancer, in a subject by detecting Bcl-2 in a biological sample from the subject, preferably a urine or blood sample. Bcl-2 may be measured using an agent that detects or binds to Bcl-2 protein or an agent that detects or binds to encoding nucleic acids, such as antibodies specifically reactive with Bcl-2 protein or a portion thereof. The invention further relates to kits for carrying out the methods of the invention. The invention further relates to a device for the rapid detection of Bcl-2 in a bodily fluid and methods for rapidly measuring Bcl-2 in a bodily fluid. | 12-29-2011 |
| 20110311473 | METHODS OF TREATING COGNITIVE IMPAIRMENT - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. | 12-22-2011 |
| 20110301159 | KINASE INHIBITOR COMPOUNDS - The disclosure relates to novel compounds that are capable of modulating Jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a Jak2 mediated disease or disorder, and methods of use and compositions thereof. | 12-08-2011 |
| 20110288890 | COMPUTER SYSTEMS AND METHODS FOR SELECTING SUBJECTS FOR CLINICAL TRIALS - Computers, computer program products, and methods for identifying a plurality of subjects for a clinical trial are provided. A candidate set of molecular profiles in a stored plurality of molecular profiles are identified. Each such profile has measurements for a discriminating set of cellular constituents that match the measurements of corresponding cellular constituents in a responder set of biological samples, thereby identifying the plurality of subjects for the trial from those subjects from which the candidate set of molecular profiles were derived. Each respective molecular profile in the stored plurality of profiles has measurements of a plurality of cellular constituents from a respective biological sample in a plurality of samples obtained from a first plurality of subjects. The discriminating set of cellular constituents is identified from those cellular constituents in the plurality of cellular constituents whose measurement values discriminates between the responder and nonresponder sets of biological samples. | 11-24-2011 |
| 20110275384 | ADAPTIVE LOCATION DATA BUFFERING FOR LOCATION-AWARE APPLICATIONS - A method of buffering location data on a mobile device. The method transmits location data packets via an unreliable protocol to a receiving device and buffers a copy of the location data packet. Periodically, the method also transmits a location data packet via a reliable protocol to the receiving device. When no acknowledgement is received from the receiving device, the location data sent via the reliable protocol is buffered to memory. Once an acknowledgement is received from the receiving device, all of the buffered location data is sent to the receiving device via an unreliable protocol. | 11-10-2011 |
| 20110274674 | ISCHEMIC TISSUE CELL THERAPY - The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina. | 11-10-2011 |
| 20110268710 | METHODS OF TREATING STROKE USING STEM CELL-LIKE MENSTRUAL BLOOD CELLS - A cell type that is a complete match of the transplant recipient appears as an optimal scenario to open treatment options to a large patient population with minimal complications. The use of autologous bone marrow or umbilical cord blood has been proposed as a good source of stem cells for cell therapy. Menstrual blood is found to be another important source of stem cells. Assays of cultured menstrual blood reveal that they express embryonic like-stem cell phenotypic markers and neuronal phenotypic markers under appropriate conditioned media. Oxygen glucose deprivation stroke models show that OGD-exposed primary rat neurons, co-cultured with menstrual blood-derived stem cells or exposed to the media from cultured menstrual blood, exhibited significantly reduced cell death. Transplantation of menstrual blood-derived stem cells, either intracerebrally or intravenously, after experimentally induced ischemic stroke in adult rats also significantly reduced behavioral and histological impairments compared to vehicle-infused rats. | 11-03-2011 |
| 20110246606 | ARCHITECTURE AND TWO-LAYERED PROTOCOL FOR REAL-TIME LOCATION-AWARE APPLICATIONS - A two-layer communication protocol that supports efficient real-time location-aware application on multiple mobile devices that must communicate with each other and/or a centralized server. The two-layer protocol includes a method of communicating data between a first mobile device and a second mobile device using a server to facilitate the communication of the data. The two-layer communication protocol also includes a method of communicating data between a first mobile device and a second mobile device using a server to facilitate the connection between the two devices. The communication of data occurs directly between the two mobile devices. Each method uses reliable, connection-oriented protocols to exchange application-level information and control signals while utilizing unreliable, connection-less protocols to communicate real-time location data. Also provided are architectures implementing these methods. | 10-06-2011 |
| 20110244570 | VOLUME EXCLUSION AGENT TO ENHANCE FORMATION OF EXTRACELLULAR MATRIX - A method of enhancing the formation of extracellular matrix in culture. Cells in culture secrete most of the collagen into the media as unprocessed procollagen, i.e., the cells do not convert procollagen to collagen. In contrast, normal extracellular matrix deposition involves procollagen processing to collagen, fibril assembly and deposition into the cell layer to form a collagenous extracellular matrix. The addition of certain growth factors and the addition of a thin layer of a certain volume exclusion agent on top of the cells dramatically enhances the conversion of procollagen to collagen and will increase the amount of collagen and extracellular matrix associated with the cells. This invention advances bioengineering of connective tissues for medical applications that require an extensive and functional extracellular matrix with high tensile strength such as those in the cornea stroma, skin, tendons, ligaments, articular cartilage and the intervertebral disks. | 10-06-2011 |
| 20110243957 | MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION - The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability. | 10-06-2011 |
| 20110236471 | PLATINUM COMPLEXES AND METHODS FOR INHIBITING TUMOR CELL PROLIFERATION - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro. | 09-29-2011 |
| 20110223608 | MOLECULAR DETECTION AND QUANTIFICATION OF ENTEROCOCCI - A primer pair and probe for the large subunit ribosomal RNA gene of | 09-15-2011 |
| 20110223154 | COMPOSITIONS INCLUDING TRICIRIBINE AND METHODS OF USE THEREOF - This invention encompasses combination therapies including TCN, TCN-P, TCN-PM and/or related compounds and one or more additional anti-cancer agents, for example, taxanes a molecule that modulates the HER2/neu (erbB2) receptor, anthracyclin compounds, epidermal growth factor receptor inhibitor compounds, one or more platinum compounds and bortezomib and derivatives thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 09-15-2011 |
| 20110217460 | SELF-ASSEMBLING, COLLAGEN-BASED MATERIAL FOR CORNEAL REPLACEMENT - A material derived from sea cucumber collagen fibrils is suitable for use in corneal replacements or as an implantable contact lens. To produce material, the collagen fibrils are centrifuged into orthogonal stacks of lamellae comprised of aligned fibrils. The resulting structure is a transparent film of arbitrary thickness very similar in structure to mammalian corneal tissue. | 09-08-2011 |
| 20110212443 | Method for determining the specific growth rate of distinct microbial populations in a non-homogeneous system - The present invention pertains to a molecular biology-based method and kit for measuring the specific growth rate (or cell doubling time) of distinct microbial populations. The method and kit can be used to analyze mixed culture samples that have been exposed to chloramphenicol or other protein synthesis inhibitors for defined times. In a preferred embodiment, the method of the invention (also referred to herein as FISH-RiboSyn) is an in situ method that utilizes fluorescence in situ hybridization (FISH) with probes that target: (1) the 5′ or 3′ end of precursor 16S rRNA; or (2) the interior region of both precursor 16S rRNA and mature 16S rRNA. Images can be captured for a defined exposure time and the average fluorescent intensity for individual cells can be determined. The rate of increase of the whole cell fluorescent intensity is used to determine the specific growth rate. The method of the invention can be attractive for rapidly measuring the specific growth rate (or cell doubling time) of distinct microbial populations within a mixed culture in industries such as environmental systems (water and wastewater treatment systems), bioremediation (optimization of conditions for microbial growth), public health (identification of rapidly growing infectious microbes), and homeland security (identification of rapidly growing bioterrorism agents). | 09-01-2011 |
| 20110201688 | N,N'-DI-P-BROMOPHENYL GUANIDINE TREATMENT FOR STROKE AT DELAYED TIMEPOINTS - 1,3 di-o-tolylguanidine (DTG) was examined as anti-stroke drug with a broad therapeutic window. DTG activates sigma 1 and 2 receptors. Administration of DTG at 24 hours post-stroke to rats reduces neurodegeneration by 85%; this is the only pharmacological agent that has been used successfully at this delayed timepoint. Treatment with DTG provides protection of neurons exposed to hypoxia and blocks activation of immune cells that are responsible for delayed neurodegeneration associated with stroke. Disclosed is an altered DTG structure, placing a bromide at the para position to increase tissue penetrance and efficacy. Results show that N,N′-di-p-bromophenyl guanidine protects cultured neurons under hypoxic conditions but is more potent than DTG. Moreover, N,N′-di-p-bromophenyl guanidine is as least as efficacious as DTG in treating rats 24 hours after experimental stroke. | 08-18-2011 |
| 20110201609 | PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS - The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds. In one embodiment, a compound of the invention has the chemical structure shown in formula I: | 08-18-2011 |
| 20110201576 | Small molecule inhibitors of stat3 with anti-tumor activity - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 08-18-2011 |
| 20110201565 | LUTEOLIN AND DIOSMIN/DIOSMETIN AS NOVEL STAT3 INHIBITORS FOR TREATING AUTISM - The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction of autistic phenotype induced by IL-6 through inhibition of STAT3 activation. | 08-18-2011 |
| 20110190315 | INDOLINE SCAFFOLD SHP-2 INHIBITORS AND CANCER TREATMENT METHOD - The subject invention concerns methods and compounds for inhibiting Shp2. In one embodiment, a compound of the invention has a chemical structure as shown in formula I or II: | 08-04-2011 |
| 20110186522 | REMOVAL OF NUISANCE ANION AND ANIONIC MATERIALS USING POLYALKYLENEIMINES SUCH AS POLYETHYLENEIMINE - The present invention features a method of removing one or more nuisance anionic materials, such as pharmaceuticals and dyes, from a solution, such as wastewater. Related aspects of the invention include an apparatus and kits for carrying out the methods of the invention. | 08-04-2011 |
| 20110166095 | CANCER PLATINUM RESISTANCE DETECTION AND SENSITIZATION METHOD - The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay. | 07-07-2011 |
| 20110160178 | HETEROSUBSTITUTED N-THIOLATED BETA-LACTAM COMPOUNDS AND METHODS OF USE - The invention relates to heterosubstituted N-thiolated beta-lactams, compositions comprising these compounds, methods for their production, and methods of use as antibiotics to inhibit the growth of bacteria. In one embodiment, the compounds have the structure shown in formula (A) or formula (B) or formula (C): | 06-30-2011 |
| 20110160089 | DNA Biochip and methods of use - The subject invention concerns materials and methods for detecting nucleic acid sequences. One aspect of the invention concerns a silicon-based “biochip” comprising nucleic acid immobilized thereon. In one embodiment, the silicon comprises microcavities. The nucleic acid to be assayed for the presence of one or more target nucleic acid sequences is immobilized on the silicon. A nucleic acid, such as an oligonucleotide probe, having a sequence substantially complementary to the target nucleic acid sequence can be used to detect the immobilized nucleic acid on the silicon. If the nucleic acid used for detection hybridizes with a target nucleic acid sequence, the hybridized sequences can be detected directly or indirectly. In an exemplified embodiment, the oligonucleotide probe can be labeled with a detectable label, for example, a fluorescent molecule. The subject invention also concerns methods for detecting a target nucleic acid using a silicon-based biochip of the invention. | 06-30-2011 |
| 20110151455 | Fish-ribosyn for antibiotic susceptibility testing - The subject invention concerns materials and methods for evaluating the susceptibility of bacterial cells to an antibiotic or other antimicrobial compound or agent. In one embodiment, a sample comprising a microbial population is exposed to an antibiotic of interest. The sample is then processed using FISH-RiboSyn methods to determine the specific growth rate of the antibiotic-exposed microbes as compared to an untreated control. The subject invention also concerns materials and methods for determining the most suitable and/or effective antibacterial treatment for a person or animal having a bacterial infection. | 06-23-2011 |
| 20110143361 | PREDICTIVE VALUE OF NUCLEAR EXCISION REPAIR GENES FOR CANCER SURVIVAL - Patients who have their cancer surgically removed are at risk for recurrence, even though currently free of disease. Lung cancer patients with higher activity of a nuclear excision repair gene called ERCC1 were at a lower risk for recurrence than patients with lower activity of ERCC1. Hence, it is possible to predict which patients are at a higher risk for recurrence after resection. This information can be used to design treatment strategies for patients determined to be at a higher risk for recurrence. Additionally, patients who are lower risk for recurrence can be saved the morbidity of further treatment. | 06-16-2011 |
| 20110142795 | METHODS OF TREATING COGNITIVE IMPAIRMENT - The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment. | 06-16-2011 |
| 20110112288 | Metal Porphyrin Catalyzed Olefin Aziridination with Sulfonyl Azides - Cobalt(II) complex of P1 [Co(P1)], a new porphyrin that was designed on the basis of potential hydrogen bonding interactions in the metal-nitrene intermediate, is a highly active catalyst for olefin aziridination with azides. The [Co(P1)]-based system can be effectively employed for different combinations of aromatic olefins and arysulfonyl azides, synthesizing various sulfonylated aziridines in excellent yields. Besides its mild catalytic conditions, the Co-catalyzed aziridination process enjoys several attributes associated with the relatively low cost of cobalt and widely accessible arylsulfonyl azides. Furthermore, it generates stable dinitrogen as the only by-product. | 05-12-2011 |
| 20110106740 | TISSUE CLASSIFICATION METHOD FOR DIAGNOSIS AND TREATMENT OF TUMORS - The present invention discloses an informational computation method for classifying objects Specifically, the invention is a system, method, and computer-readable media for classifying tumors using a nonparametric statistical classifier in conjunction with an artificial neural network. The invention classifies unknown tumor types based on the correlation of unknown tumor's genetic expression compared to the genetic expression of know tumor types by first performing a nonparametric statistical analysis on the know data, training a artificial neural network with the known data, and then inputting the unknown tumor data into the neural network to calculate the probability that the sample tumor is a member of a class of tumors. By using a statistical classifier in conjunction with a neural network, the invention classifies unknown tumors more accurately then conventionally possible. Advantageously, by using a variety of tumor genetic expression data sets, including both published data sets and generated data sets, a tumor classifier, robust and accurate enough for clinical application, is provided. | 05-05-2011 |
| 20110104249 | Oncotherapeutic Application of Inhibitors of High-Affinity Glucose Transporters - The subject invention concerns materials and methods for treating oncological disorders in a person or animal using any agent or compound that inhibits uptake of glucose into a cell. The subject invention also concerns methods for inducing apoptosis and inhibiting the proliferation or survival of a cell. In one embodiment, the methods comprise administering an effective amount of an agent or compound that inhibits the activity of one or more glucose transporter proteins, such as Glut-1. An antibody that binds to and inhibits a glucose transporter protein can be used in the present methods. | 05-05-2011 |
| 20110092567 | Cannabinoid 2 (Cb2) Receptor Gene Promoter and Unique RNA Transcripts in B Cells and Methods of Use - Cannabinoid receptor 2 (CB | 04-21-2011 |
| 20110091481 | BIOMARKERS FOR PREDICTING RESPONSE TO IMMUNOSUPPRESSIVE THERAPY - The subject invention concerns methods and materials for assessing a patient's likelihood of responsiveness to an immunosuppressive therapy. The subject invention is contemplated for use with patients having an autoimmune disorder. In an exemplified embodiment, the methods of the invention are used for assessing and/or treating a patient with MDS. In one embodiment, a method of the invention comprises analyzing T cells of a patient for dysregulation of CD4 | 04-21-2011 |
| 20110067606 | FOLDING ARMREST TRAY FOR WHEELCHAIRS - A tray assembly mounted on a wheelchair. A housing containing the tray is mounted along the side of the chair arm. The tray assembly has a tray surface moveable between a stowed and unstowed position. | 03-24-2011 |
| 20110064704 | SHIP-DEFICIENCY TO INCREASE MEGAKARYOCYTE AND PLATELET PRODUCTION - A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced. | 03-17-2011 |
| 20110059462 | AUTOMATED PARTICULATE CONCENTRATION SYSTEM - An automated system for concentrating potentially harmful substances from various water types or other non-viscous liquids to facilitate detection of those substances is disclosed herein. The automated system comprises a water pressure driven or pump driven concentration unit that filters the test fluid through a hollow-fiber filter. Material collected on the filter is backflushed into a collection vessel by passing a small volume of sterile solution through the filter in the reverse direction. The automated system can be configured to be portable or to be integrated into a continuous liquid stream for online monitoring of test fluids. Optionally, an electronic signal at the end of the backflush sequence triggers a detector, such as an automated array biosensor, to begin processing and analyzing the sample. | 03-10-2011 |
| 20110059137 | CHEMOKINE GENE-MODIFIED CELLS FOR CANCER IMMUNOTHERAPY - Described herein are methods of cancer immunotherapy, particularly compositions comprising genetically-modified cells that express macrophage colony stimulating factor (GM-CSF), CD40 ligand (CD40L), and chemokine C—C motif ligand 21 (CCL21), wherein the population of cells comprises bystander cells and target cancer cells, and methods of making these compositions and treating cancer using these compositions. | 03-10-2011 |
| 20110058721 | METHOD AND APPARATUS FOR PULMONARY VENTILATION IMAGING USING LOCAL VOLUME CHANGES - The invention provides a novel method of high-resolution quantifiable pulmonary regional ventilation imaging using a package of computer programs, including deformable image registration and local volume change calculation on 4-D or breath-hold CT images. High resolution 3D ventilation images have been generated using this technique with superior quality. The deformation matrices between different respiration phases are calculated using deformable image registration and applied to calculate local volume change ΔV between respiration phases. The invention provides less image-noise and mismatch sensitivity than other techniques based on CT images, and is less expensive than nuclear medicine imaging. Implemented clinically, the method can derive a patient's pulmonary ventilation information from the same set of 4-D CT images, providing a cheaper but more accurate method to generate clinical lung ventilation image. Such information can be utilized in treatment planning sparing functional lung volumes without additional procedure and cost for lung functional imaging. | 03-10-2011 |
| 20110053977 | SMALL MOLECULE E2F INHIBITOR - A small molecular inhibitor of E2F (HLM006474) was identified using a computer-based virtual screen and the known crystal structure of the DNA bound E2F4/DP2 heterodimer. Treatment of multiple cell lines resulted in the loss of intracellular E2F4 DNA-binding activity. Overnight exposure to HLM006474 resulted in down regulation of total E2F4 protein as well as several known E2F targets. The effects of treatment on different cell lines included a reduction in cell proliferation and an increase in apoptosis. Apoptosis was induced in a manner distinct from cisplatin and doxorubicin. E2F4-null MEFs were less sensitive than wildtype counterparts to the apoptosis-inducing activity of the compound revealing its biological specificity. A375 cells were extremely sensitive to the apoptosis-inducing activity of the compound in two-dimensional culture and HLM006474 was a potent inhibitor of melanocytes proliferation and subsequent invasion in a three-dimensional tissue culture model system. | 03-03-2011 |
| 20110053187 | SILICA-BASED MATERIAL FOR DETECTION AND ISOLATION OF CHITIN AND CHITIN-CONTAINING MICROORGANISMS - The subject invention provides silica-based material that has high affinity to chitin, chitin derivatives and chitin-containing microorganisms at an acidic pH. In an embodiment, the silica-based material surface comprises glass. Also provided are methods for preparing the subject silica-based chitin-binding material. In addition, the subject invention provides rapid, specific, sensitive, accurate and convenient methods for detection, isolation and purification of chitin, chitin derivatives and chitin-containing microorganisms. | 03-03-2011 |
| 20110052601 | COMPOSITIONS COMPRISING ANTI-ICAM-1 ANTIBODIES - There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding. | 03-03-2011 |
| 20110052558 | MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES - The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence. | 03-03-2011 |
| 20110052546 | Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation - The instant invention teaches the inhibition of SHIP expression, or function for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such as leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary). | 03-03-2011 |
| 20110046002 | Seven Gene Breast Cancer Predictor - The invention provides a molecular marker set that can be used for prognosis of breast cancer in a patient using histologically normal tissue. The invention also provides methods for evaluating prognosis of breast cancer in a patient based on a molecular molecular signature. | 02-24-2011 |
| 20110039777 | CANCER TREATMENT USING NATRIURETIC PEPTIDES - The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention. | 02-17-2011 |
| 20110034386 | DENDROASPIS NATRIURETIC PEPTIDE FOR TREATMENT OF CANCER - Disclosed is a method of inhibiting the growth of a cancer cell using | 02-10-2011 |
| 20110028565 | EXO-S-MECAMYLAMINE FORMULATION AND USE IN TREATMENT - A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders. | 02-03-2011 |
| 20110027884 | COMBINATION OF INSULIN AND ASCORBATE TO ENHANCE WOUND HEALING - Provided is a method of stimulating collagen synthesis and proteoglycan (lumican and keratocan) accumulation. Collagenase isolated keratocytes were cultured with or without insulin with or without ascorbate. Insulin stimulates the synthesis of collagen but does not affect the accumulation of lumican and keratocan. Insulin plus ascorbate, however, stimulates the synthesis of collagen and increased the accumulation of these proteoglycans. The accumulation of PGDS, a KSPG that does not interact with collagen, is not affected by ascorbate. Only the collagen made in the presence of ascorbate was pepsin resistant. EDB overrode the effects of ascorbate on pepsin resistance and proteoglycan accumulation. | 02-03-2011 |
| 20110021375 | Sphingosine 1-Phosphate Receptor Gene, SPPR - A novel sphingosine 1-phosphate receptor gene, herein termed sppr, and its splice variants. Sppr is up-regulated in LGL and is useful, for example, in the diagnosis and treatment of certain lymphoproliferative, neurodegenerative and autoimmune diseases. | 01-27-2011 |
| 20110021357 | CONTROL OF HARMFUL ALGAL BLOOMS BY INDUCTION OF PROGRAMMED CELL DEATH - The subject invention pertains to compositions, apparatus, and methods for controlling harmful algae and harmful algal bloom (HAB) based on the induction of the programmed cell death (PCD; apoptosis) pathway in the harmful algae, and to kits for determining algal susceptibility to PCD induction. | 01-27-2011 |
| 20100331625 | ENDOSCOPIC OVERTUBE - An over-tube was developed for receiving and guiding endoscopic instruments into a patient's anus, through the colon, and into the peritoneum. The over-tube has a flexible sheath adapted for insertion into the anus through the colon and out the peritoneum of a patient. A stiffened region is used to protect the colonic wall from injury during insertion of medical instruments through the patient's lower gastrointestinal tract. The proximal end of the over-tube is surrounded by two narrow inflatable balloons on either side of the colotomy to keep the device in place with its lumen open into the peritoneum and further prevent leakage of insufflation. The device may comprise two channels, one for duel channel endoscopes and larger medical instruments or single lumen endoscopes, and an additional channel for surgical instruments. A distal valve prevents insufflation leakage, making the device especially useful in NOTES surgeries. | 12-30-2010 |
| 20100331285 | Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same - A polymorph of aspirin is provided by the present invention. Methods of making and using the same are also provided. | 12-30-2010 |
| 20100316704 | PLATINUM COMPLEXES AND METHODS OF USE - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro. | 12-16-2010 |
| 20100310645 | METHODS FOR INHIBITING TUMOR CELL PROLIFERATION - The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes. | 12-09-2010 |
| 20100305058 | INDIVIDUALIZED CANCER TREATMENTS - The invention provides for compositions and methods for predicting an individual's responsitivity to cancer treatments and methods of treating cancer. In certain embodiments, the invention provides compositions and methods for predicting an individual's responsitivity to chemotherapeutics, including platinum-based chemotherapeutics, to treat cancers such as ovarian cancer. Furthermore, the invention provides for compositions and methods for predicting an individual's responsivity to salvage therapeutic agents. By predicting if an individual will or will not respond to platinum-based chemotherapeutics, a physician can reduce side effects and toxicity by administering a particular additional salvage therapeutic agent. This type of personalized medical treatment for ovarian cancer allows for more efficient treatment of individuals suffering from ovarian cancer. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for personalizing cancer treatments, and provides methods of conducting a diagnostic business for personalizing cancer treatments. | 12-02-2010 |
| 20100297061 | STAT3 ANTAGONISTS AND THEIR USES AS VACCINES AGAINST CANCER - The present invention relates to methods for treating and/or preventing cancer. In particular the present invention relates to ex vivo immunotherapeutic methods. The methods comprise decreasing Stat3 (signal transducer and activator of transcirption3) expression and/or function in tumor cells and the administration of such cells to a subject in need of treatment and/or prevention. Other methods of the invention comprise activation T-cells by co-culturing the T-cells with the tumor cells with decreased Stat3 expression or function. The invention further encompasses methods comprising decreasing Stat3 expression or function in antigen-presenting cells and co-administering tumor cells and the antigen-presenting cells with decreased Stat3 function to a patient. The invention further relates to methods for stimulating dendritic cell differentiation. | 11-25-2010 |
| 20100292451 | METHOD FOR DIAGNOSING SELECTED ADENOCARCINOMAS - A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis. | 11-18-2010 |
| 20100292087 | METHOD OF PREDICTING CHEMOTHERAPEUTIC RESPONSIVENESS OF CANCER - Disclosed is a method of predicting clinical tumor outcome by providing gene expression from a tumor sample. The method utilizes a novel genetic screen to identify genes that contribute to chemotherapeutic responsiveness, using formalin fixed paraffin embedded clinical samples of epithelial cancer, specifically serous ovarian cancer. The method is useful in predicting tumor responsiveness to chemotherapeutics, including alkylating agents, cisplatin, antimetabolites, plant alkaloids, and antitumor antibiotics. A microarray screen showed formalin fixed paraffin embedded samples can identify genes related to chemotherapeutic response with 86% efficiency. | 11-18-2010 |
| 20100286249 | Micro-RNAS Modulating Immunity and Inflammation - MicroRNAs are shown to be up- and/or down-regulated in inflammation and immune cells using a mouse model of asthma and regulatory T cells as source of RNA, respectively. Modulating the expression of these microRNAs can be effective in redirecting inflammation and immunity and hence, can be beneficial as biomarkers or as therapeutic agents against diverse human immunologic and inflammatory diseases. | 11-11-2010 |
| 20100280437 | MULTICHANNEL TROCAR - A multi-channel trocar developed for use in ‘minimal-access surgery/single incision laparoscopic surgery. The trocar permits surgical access of two or more articulating laparoscopic instruments or scopes through one skin incision using a dividing membrane to separate the working channels. This allows maximal use of robotic technology and permits more degrees of freedom at the operative site. The trocar is inserted through one single skin incision, in the usual manner. The trocar relocates the fulcrum and focal point of motion to the abdominal wall when using a set of interacting and interlocking diaphragms | 11-04-2010 |
| 20100278920 | Polyacrylate Nanoparticle Drug Delivery - Drug delivery of resistance reversal agents by polyacrylate nanoparticles for treatment of drug (e.g. chloroquine) resistant malaria. Also provided are drug delivery by polyacrylate nanoparticles of ciprofloxacin for treatment of anthrax. | 11-04-2010 |
| 20100274084 | TRANS-ENDOSCOPIC HYDRAULIC BALLOON APPARATUS - A trans-endoscopic hydraulic balloon dilation apparatus includes a fluid reservoir containing a hydraulic fluid. A shaft has a lumen in fluid communication with a leading end of the fluid reservoir. A balloon is mounted on the shaft and an opening in the shaft enables hydraulic fluid to flow through the opening into or from the balloon. A piston secured to a leading end of a piston rod is slideably positioned within a lumen of the fluid reservoir. A hub secured to a trailing end of the fluid reservoir is centrally apertured to accommodate the piston rod so that a trailing end of the piston rod is external to the fluid reservoir. Displacement of the piston rod in a trailing-to-leading direction causes expansion of the balloon. Displacement of the piston rod in a leading-to-trailing direction causes deflation of the balloon. The piston can be locked into any position. | 10-28-2010 |
| 20100267733 | Synergistic Modulation of Microglial Activation by Nicotine and THC - Treatment of microglial cells with nicotine and THC synergistically attenuate the microglial activation. Using microglial activation, the combination of THC and nicotine interact synergistically reduced LPS induced TNF-α release, showing that the combination of THC and nicotine clinically have greater efficacy in reducing neuroinflammation with less side effects than either drug given alone. CD40 signaling was found critically involved in pathological activation of microglial cells. This invention is also relevant to peripheral inflammation as well thru macrophages. In addition, other cannabinoids and other nicotinic-like medications currently in development are also covered under this discovery. | 10-21-2010 |
| 20100266548 | LPS-Responsive CHS1/Beige-Like Anchor Gene and Therapeutic Applications Thereof - The present invention relates to a novel LPS-responsive and Beige-like Anchor gene (lrba), variants of the lrba gene, fragments of the lrba gene, and polypeptides encoded thereby. The subject invention also pertains to lrba interfering RNA, and uses thereof. In another aspect, the present invention also includes methods of inhibiting tumor growth in a patient by suppressing lrba function. | 10-21-2010 |
| 20100260730 | SHIP-Deficiency to Increase Megakaryocyte Progenitor Production - The invention concerns a method for increasing megakaryocyte and megakaryocyte progenitor numbers in vitro or in vivo by suppressing SH2-containing inositol-5-phosphatase (SHIP) function in megakaryocytes or megakaryocyte progenitors expressing the SHIP gene. SHIP function can be suppressed by administering an interfering RNA, or other SHIP inhibitor, to the megakaryocytes or megakaryocyte progenitors in vitro or in vivo. | 10-14-2010 |
| 20100254973 | Materials and Methods for Diagnosis of Asthma - The present invention pertains to materials and methods for diagnosing and/or determining the prognosis and likelihood of developing asthma. In one embodiment, methods of the invention comprise the use of single nucleotide polymorphic markers of asthma. Markers of the invention are present in the atria natriuretic peptide (NPPA) gene, and serve as a marker for genetic susceptibility of a person or animal in developing asthma. | 10-07-2010 |
| 20100250957 | Method of Authenticating a User on a Network - A method of controlling access to electronic information is provided. The method requires the use of a portable token adapted to read and verify a user's biometric data in order to view encrypted files or data fields. If the proper biometric data is entered into the token, the user is presented with a unique and dynamic password for logon. The unique password is displayed on a small LCD screen on the token. Access to the protected information is allowed once the unique password is verified by the enterprise system containing the encrypted. | 09-30-2010 |
| 20100249757 | Method of Electrogenically Controlling Pump Molecules - Activation of electrogenic pump molecules can be realized by a dynamic entrainment procedure which includes two steps: synchronization of individual pump molecules to work at the same pumping pace, and gradual modulation of the synchronization frequency. Na/K pump molecules were used as an example in a physiological operating mode by applying the concept of an electronic synchrotron to the biological system. It was shown that individual Na/K pump molecules can be synchronized by a well designed oscillating electric field. The synchronized pump currents show separated inward and outward pump currents and a magnitude ratio of 3:2 reflecting stoichiometric number of the pump molecules. | 09-30-2010 |
| 20100249230 | ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES - Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by | 09-30-2010 |
| 20100248328 | HYPERACTIVE VARIANTS OF 5-AMINOLEVULINATE SYNTHASE AND METHODS OF USE - The rate of porphyrin biosynthesis in mammals is controlled by the activity of the pyridoxal 5′-phosphate-dependent enzyme 5-aminolevulinate synthase. Assuming the turnover in this enzyme is controlled by conformational dynamics at a highly conserved active site loop, a variant library was constructed by targeting imperfectly conserved non-catalytic loop residues and the effects on product and porphyrin production were examined. Functional loop variants of the enzyme were tested for porphyrin fluorescence, which varied widely and thus facilitated identification of clones encoding unusually active enzyme variants. Nine loop variants leading to high in vivo porphyrin production were purified and characterized kinetically. Steady-state catalytic efficiencies for the two substrates were increased by up to one hundred-fold. The data support the postulate that the active site loop controls the rate of product and porphyrin production in vivo and suggest the possibility of an as yet undiscovered means of allosteric regulation. | 09-30-2010 |
| 20100247427 | Methods of inhibiting cell growth and methods of enhancing radiation responses - Provided herein are methods of enhancing the radiation response of a cell expressing activated Stat1, Stat3, or Stat5. Methods for synergistically affecting a cell expressing activated Stat1, Stat3, or Stat5 are also described. The described methods may also be used to synergistically affect or enhance the radiation response of a cell in a subject. | 09-30-2010 |
| 20100240540 | GENOTYPIC TUMOR PROGRESSION CLASSIFIER AND PREDICTOR - Actively dividing tumors appear to progress to a life threatening condition more rapidly than slowly dividing tumors. Assessing actively dividing tumors currently involves a manual assessment of the number of mitotic cells in a histological slide prepared from the tumor and assessed by a trained pathologist. Disclosed is a method for using cumulative information from a series of expressed genes to determine tumor prognosis. This cumulative information can be used to categorize tumor samples into high mitotic states or low mitotic states using a mathematical algorithm and gene expression data derived from microarrays or quantitative-Polymerase Chain Reaction (Q-PCR) data. The specific mathematical description outlines how the algorithm assesses the most informative subset of genes from the full list of genes during the assessment of each sample. | 09-23-2010 |
| 20100234891 | TRANSLATIONAL MANIPULATION POLYAXIAL SCREW HEAD - A novel surgical screw is presented as a polyaxial, multiaxial, or monoaxial screw. The polyaxial screw allows versatile angulation between a bone anchor section and a screw body and allows the surgeon to attach a rod to the invention in a top-loading manner and manipulate the rod to accommodate a patient's body and the surgical goals. The screw uses a rod saddle to seat a rod, and permits the surgeon to sagitally manipulate the rod. After implantation of the screw and insertion of the rod, a locking screw is used to fix the angle and position of the rod and screw body. | 09-16-2010 |
| 20100233969 | RECONFIGURABLE CHAMBER FOR EMULATING MULTIPATH FADING - Disclosed is a compact reconfigurable channel emulator, which may be used to emulate severe fading environments and test wireless systems and subsystems for operation in severe channel environments. Examples include radios, coding schemes, diversity methods and antennas. In particular, the chamber is well suited to test hardware associated with wireless sensor deployments for these tend to be susceptible to severe fading scenarios. Moreover, the invention is significantly smaller than traditional testing instruments, and with its automation, reduces electromagnetic interference and electromagnetic compatibility testing time and costs. | 09-16-2010 |
| 20100233712 | Method for Early Detection of Cancers - The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition. | 09-16-2010 |
| 20100227849 | LEUKEMIA TREATMENT METHOD AND COMPOSITION - A method of inducing high anti-leukemia activity responsive to the combination of hydroxamic acid analogue histone deacetylase inhibitors and PKC412 against human acute leukemia characterized as expressing phosphorylated (p)FLT3 kinase by a novel flow cytometry-based assay. | 09-09-2010 |
| 20100227811 | FARNESYLAMINE DERIVATIVES AND METHODS OF USE - The present invention concerns farnesylamine derivatives, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of ras-mediated signal transduction and inhibitors of aberrant cell growth, e.g., as anti-cancer agents, as well as anti-fungal agents. Other non-malignant diseases characterized by proliferation of cells that may be treated using the farneylamine derivatives of the include, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. | 09-09-2010 |
| 20100222764 | Intracranial Catheter and Methods of Use - A catheter assembly for intracranial treatment of a subject that includes an outer tube that may be connected to an infusion or osmotic pump and delivered through a bendable catheter to the target brain site of the subject. The assembly facilitates regular accurate placement of drug or compound delivery at the tissue region without additional contact and minimizes trauma to the subject. | 09-02-2010 |
| 20100221233 | COMPOSITIONS AND METHODS FOR ENHANCING NEUROPROTECTION VIA ADMINISTRATION OF STEM CELLS AND BLOOD BRAIN BARRIER PERMEABILIZERS - The present invention provides compositions and methods for enhancing the neuroprotective effect of umbilical cord blood cells. More particularly, the present invention provides methods of treating neurodegenerative disorders by administering umbilical cord blood cells and a substance capable of permeabilizing the blood brain barrier. In one embodiment, the blood brain barrier permeabilizer is mannitol. In another embodiment, the blood brain barrier permeabilizer is Cereport. | 09-02-2010 |
| 20100216992 | MIMETIC COMPOSITIONS AND THE PRODUCTION THEREOF - The present invention generally relates to compositions including six membered heterocyclic 1,4-diaza-2-one moieties covalently bonded by a hydrazine bond and processes for producing the same. The compositions of the present invention may be utilized as peptido- and/or proteomimetics, for example,' in connection with alpha-helical proteins, like Bcl-2 proteins. | 08-26-2010 |
| 20100210516 | Growth Factor Binding Molecules - Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In one embodiment a platelet-derived growth factor binding molecule is disclosed that is used to inhibit tumor growth and angiogenesis in solid tumors. | 08-19-2010 |
| 20100204337 | ANTIBACTERIAL S-HETEROSUBSTITUTED DISULFIDES - Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including | 08-12-2010 |
| 20100204204 | NUTRACEUTICAL CO-CRYSTAL COMPOSITIONS - Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs. | 08-12-2010 |
| 20100196915 | Method of Detecting Oncogenesis of Hematopoietic Cells - Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events. | 08-05-2010 |
| 20100184851 | INHIBITION OF CELL PROLIFERATION - Compounds of formula (I) and (II) are provided as modulators of Rb:Raf-1 interactions which are potent, selective disruptors of Rb:Raf-1 binding. Therapeutic methods of using the compounds, for example for treating or ameliorating a cell proliferation disorder such as cancer, are provided. | 07-22-2010 |
| 20100184065 | Method of Predicting Non-Response to First Line Chemotherapy - The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor. | 07-22-2010 |
| 20100183521 | METHODS OF DETECTING AND TREATING COLON DISORDERS - The subject invention pertains to a method of detecting colon disorders including inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, based on underexpression of Lipopolysaccharide Responsive Beige-like Anchor (LRBA). Advantageously, the invention may be used to test for inflammatory bowel disease using a blood sample from a subject before a more invasive test for colon disorders is employed. The invention also pertains to methods of treating a colon disorder in a subject in which the colon disorder is detected. | 07-22-2010 |
| 20100180953 | Thermally Induced Single-Use Valves and Method of Use - In accordance with an embodiment of the present invention, a thermally induced single-use valve is provided including a silicon wafer having a top surface and a bottom surface and at least one cavity formed in the bottom surface of the wafer, a thermally deformable membrane suspended across the cavity on the top surface of the wafer and at least one resistive element patterned on top of the thermally deformable membrane. | 07-22-2010 |
| 20100179658 | Vertebral Body Cage - A intervertebral body device for supporting adjacent vertebrae includes a vertebral body member having at least one containment portion and one communicating portion. The containment portion and communication portion provide two distinct functional regions within the cage. One region of the cage provides for the use of a biologic material, and the region of the cage provides holes in the side or the front of the cage in order to allow bony ingrowth into that portion of the cage. Where numerous segments are needed, these components can be arranged in any combination. | 07-15-2010 |
| 20100173985 | Polyphenol proteasome inhibitors, synthesis, and methods of use - The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers. | 07-08-2010 |
| 20100173984 | EPIGALLOCATECHIN-3-GALLATE CRYSTAL COMPOSITIONS - Crystalline epigallocatechin-3-gallate compositions and methods of use. | 07-08-2010 |
| 20100172879 | AMYLOID BETA PEPTIDES AND METHODS OF USE - The application describes several mutant amyloid beta peptides and specific regions which are useful in the therapeutic and diagnostic of neurological diseases. The application further describes methods of using these mutant peptides as treatment and reagents for diagnosis of diseases. The application further describes diagnostic kits and pharmaceutical compositions for use in therapy to treat neurological diseases including but not limited to Alzheimer's disease and various forms of mild cognitive impairments. | 07-08-2010 |
| 20100152857 | Asymmetric Disc Distracting Cage - An inter-vertebral cage with a wedge shape eccentrically located on the leading end of the cage. The ectopically shaped leading edge of this embodiment facilitates easier interbody spacer placement with less risk of nerve injury, as well as with likely decreased risk of destruction of the end plate during the distraction process when the interbody cage is impacted. | 06-17-2010 |
| 20100150882 | HUCBC TREATMENT OF AMYLOID ASSOCIATED DISEASE - Administration of human umbilical cord blood cells (HUCBC) or HUCBC-derived plasma is used to treat amyloid-based diseases, such as Alzheimer's disease, Huntington's disease, cerebral amyloid antigopathy, and type-II diabetes. Modulating inflammatory reactions by infusing HUCBC resulted in a marked reduction of amyloid plaques and immune-associated cellular damage. HUCBC infusion also significantly reduced cerebral amyloid angiopathy in mice models. These effects were associated with suppression of the CD40-CD40L interaction and a reduction in surface expressed CD-40 was observed on immune cells. Further, Aβ phagocytic activity was increased and soluble and insoluble Aβ protein levels were modulated by treatment. HUCBC-infused sera also significantly increased phagocytosis of Aβ | 06-17-2010 |
| 20100144841 | CONTROL OF NK CELL FUNCTION AND SURVIVAL BY MODULATION OF SHIP ACTIVITY - Inhibition of dendritic cell function in solid organ grafts or allogeneic bone marrow transplants prior to or during engraftment by blocking SH2-containing inositol phosphatase (SHIP) expression or function is taught as a method of abrogating immune rejection and thereby increasing the efficacy of engraftment of an allogeneic bone marrow transplant or solid organ allograft or xenograft. Also disclosed is a transgenic mouse having the genotype SHIP | 06-10-2010 |
| 20100143897 | Materials and Methods for Assaying for Glyoxylate - The subject invention concerns enzyme-based methods for detecting and assaying for glyoxylate. In particular, the invention is directed to methods for assaying for glyoxylate produced by the reaction of peptidylglycine α-amidating monooxygenase (PAM). The subject invention also concerns methods for assaying for the enzyme peptidylglycine α-amidating monooxygenase. The detection of glyoxylate using the present invention is indicative of the presence of PAM. The subject invention also concerns methods for screening for peptide hormones and any N-acyl-glycine or N-aryl-glycine conjugated molecule. | 06-10-2010 |
| 20100136063 | Immunotherapy for Treatment of Amyloid-Related Disorders Using Encapsulated Beta-Amyloid Peptides - The present invention relates to the field of polymer chemistry and more particularly to encapsulated peptides and uses thereof. | 06-03-2010 |
| 20100130821 | ENDOSCOPIC OVERTUBE - An endoscopic guide for natural orifice transluminal endoscopic surgery. The device is a semi-flexible over-tube extending from the incisors through stomach and into the peritoneum. The over-tube has an inflatable balloon at its midpoint to occlude the esophageal lumen and prevent potential reflux of gastric content into the esophagus. The distal end is surrounded by two narrow inflatable balloons that are utilized on either side of the gastrotomy to keep the device in place with its lumen open into the peritoneum. The over-tube has a valve at the proximal opening that prevents leakage or peritoneal insufflation. The over-tube sheaths and protects the esophagus and guides instruments into the peritoneum. This device avoids re-intubation of the esophagus, promotes safe and easy access with increased efficiency and accuracy of insertion of the endoscope and other instruments, minimizes risks of perforation or other mucosal injuries, and allows secure control of the gastrotomy. | 05-27-2010 |
| 20100118465 | Method of Manufacturing Silicon Topological Capacitors - In accordance with the present invention, a novel method to fabricate topological capacitors is provided. The fabrication method of the instant invention is based upon a reversed surface topology utilizing deep reactive ion etching to establish conductive capacitive elements and non-conductive capacitive element groups. | 05-13-2010 |
| 20100104504 | Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation - The subject invention concerns materials and methods for treating and/or preventing diseases associated with accumulation of Aβ peptide in neural tissue. The subject invention also concerns materials and methods for treating and/or preventing stress disorders, such as post-traumatic stress disorder (PTSD). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of cotinine, or a pharmaceutically acceptable salt thereof, to a person or animal in need of treatment. The methods of the invention can be used to prevent and/or treat Alzheimer's disease, Parkinson's disease, and/or Down's syndrome. The subject invention also concerns compositions that comprise cotinine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or adjuvant. | 04-29-2010 |
| 20100087063 | NANOMETER-SCALE ELECTROMECHANICAL SWITCH AND FABRICATION PROCESS - The present invention describes nano-scale fabrication technique used to create a sub-micron wide gap across the center conductor of a coplanar waveguide transmission line configured in a fixed-fixed beam arrangement, resulting in a pair of opposing cantilever beams that comprise an electro-mechanical switch. Accordingly, a nanometer-scale mechanical switch with very high switching speed and low actuation voltage has been developed. This switch is intended primarily for application in the RF/microwave/wireless industry. | 04-08-2010 |
| 20100081838 | Cobalt-Catalyzed Asymmetric Cyclopropanation of Alkenes with alpha-Nitrodiazoacetates - A process for the cyclopropanation of olefins with a metal porphyrin catalyst and an acceptor/acceptor substituted diazo reagent. | 04-01-2010 |
| 20100076786 | Computer System and Computer-Implemented Method for Providing Personalized Health Information for Multiple Patients and Caregivers - Personalized health information is provided by maintaining a patient profile over time and matching information from the patient profile to appropriate patient-centric information related to that patient's specific medical condition. The patient profile can include a variety of medical information. The patient profile is matched, for example, to patient-centric options for care, clinical trials for which the patient is eligible, drug treatment regimens directly related to each patient's specific condition, scheduling of the treatments, survivorship plans and data, information about managing symptoms, nutritional information, rehabilitation recommendations, possible adverse events based on specific treatments to monitor, and personalized education and information. The patient profile can be populated with information from a database, such as one associated with a cancer registry. | 03-25-2010 |
| 20100076239 | ASYMMETRIC CYCLOPROPANATION OF ELECTRON-DEFICIENT OLEFINS WITH DIAZO REAGENTS - Cobalt-catalyzed asymmetric cyclopropanation of electron-deficient olefins. | 03-25-2010 |
| 20100070171 | System and Method for Real-Time Travel Path Prediction and Automatic Incident Alerts - A path prediction method that uses a commuter's travel patterns to predict their route and destination, and transmit road advisories via a GPS-enabled device. Once the user's location data is transmitted via a GPS-enabled device it is then catalogued and stored in a GIS database. The user's current travel path is then compared to their path history and statistics and a destination is determined based on related spatial and time properties. A warning is then automatically delivered to the user if there is an accident along their predicted path, without requiring any request or input form the user. | 03-18-2010 |
| 20100069479 | NEURODEGENERATIVE DISEASE TREATMENT USING JAK/STAT INHIBITION - The invention relates to treatment of neurodegenerative diseases with JAK/STAT pathway inhibitors to eliminate extracellular cell signaling events leading to cell cycle abrogation and/or apoptosis. Primary neurons were administered neurotoxic proteins, such as gp120, Tat, or gp120 and Tat, with or without IFN-γ added, resulting in neuronal death, and simulated neurodegenerative diseases. The neurodegenerative disease is treated using a JAK/STAT pathway inhibitor, including (—)-epigallocatechin-3-gallate (EGCG), to modulate JAK1 or STAT1 phosphorylation, resulting in resistance to gp120 or Tat neurotoxicity. The invention may be used to treat neurons afflicted with HIV-associated Dementia, multiple sclerosis, Alzheimer's Disease, Parkinson's Disease, amyotrophic lateral sclerosis, or Pick's Disease, and may act in conjunction with antiviral treatment, like HAART. | 03-18-2010 |
| 20100069475 | METHOD OF ACTIVATING NK CELLS - The present invention provides a method of mediating hypo-activation of NK cells. Methods of the present invention comprise administering to a subject an effective amount of broad acting phosphotase inhibitor, such as sodium orthovanadate, SHP specific inhibitor. In one embodiment, the SHP specific inhibitor is NSC119910. | 03-18-2010 |
| 20100068264 | NIOSOME-HYDROGEL DRUG DELIVERY SYSTEM - Localized drug delivery systems are effective means to administer therapeutic concentrations and controlled release of drugs. A delivery system consisting of non-ionic surfactant vesicles (niosomes) packaged within a biodegradable, temperature and pH sensitive hydrogel network was developed. Drug behaviors were modeled using a fluorescent dye with similar physical properties as therapeutic drugs for cancer. The niosomes were embedded into a biodegradable hydrogel providing a stable niosome environment. A cross linked chitosan was used as the hydrogel, which is a liquid at room temperature, and gels inside the body. Depending on the conditions to which individual niosomes are exposed, the release rate can be controlled to last from 24 hours to more than 3 months. | 03-18-2010 |
| 20100063465 | BLADDER DRAINAGE AID - Provided is a bladder drainage aid which attaches to the end of Foley Catheter and removes the need for a catheter bag. In a preferred embodiment, the device is a spring-loaded valve with an inflow tube and an outflow tube. The inflow tube connects to the external end of a catheter. The outflow tube can be aimed by the patient. When pressed, the valve opens, allowing the fluid to flow there through. When released, the piston of the valve cuts off fluid flow. The valve cap allows ease of use and the device can be operated with two fingers of one hand. The patient can wear the drainage aid discretely and empty the bladder directly and discretely, such as into a toilet. | 03-11-2010 |
| 20100063137 | Cytotoxin Compound And Method of Isolation - The present invention concerns compounds derived from tunicates of the species | 03-11-2010 |
| 20100058843 | SELF-PROPELLED SENSOR APPARATUS FOR IN SITU ANALYSIS OF ENVIROMENTAL PARAMETERS - A submersible, self-propelled apparatus for analyzing a component contained in a liquid medium. The submersible, self-propelled apparatus uses kinetic energy of the apparatus to drive a liquid under analysis through the apparatus. This is accomplished by use of a conveyance system that is attached to the analytical system of the apparatus. A sensor system is used to analyze the component collected within the confines of an analysis chamber, a part of the analysis system. The invention also includes a method of using the analytical apparatus. | 03-11-2010 |
| 20100058842 | SELF-PROPELLED SENSOR APPARATUS FOR IN SITU ANALYSIS OF ENVIROMENTAL PARAMETERS - A self-propelled apparatus for analyzing a component contained in a fluid medium. The self-propelled apparatus uses kinetic energy of the apparatus to drive a fluid under analysis through the apparatus. This is accomplished by use of a conveyance system that is attached to the analytical system of the apparatus. A sensor system is used to analyze the component collected within the confines of an analysis chamber, a part of the analysis system. The invention also includes a method of using the analytical apparatus. | 03-11-2010 |
| 20100040558 | GREEN TEA POLYPHENOL ALPHA SECRETASE ENHANCERS AND METHODS OF USE - The subject invention concerns materials and methods for treating or preventing a neurodegenerative condition or disease associated with β-amyloid peptide deposition in neural tissue in a person or animal by administering a therapeutically effective amount of a polyphenol, or an analog, isomer, metabolite, or prodrug thereof, that increases expression or activity of a protein that exhibits α-secretase activity. The subject invention also provides methods to increase α-secretase expression and/or activity in cells by administering polyphenol flavonoids like (−)-epigallocatechin-3-gallate (EGCG) and epicatechin (EC), two polyphenols derived from green tea and other plants and that can be produced synthetically. Furthermore, there are provided methods to decrease or inhibit the production of Aβ | 02-18-2010 |
| 20100009397 | SUBSTRATE-MIMETIC AKT INHIBITOR - Disclosed herein is a species of peptide and non-peptide inhibitors of Akt, an oncogenic protein. Beginning with a residue of Akt target substrate GSK-3, the functional domains of the GSK-3 residue were characterized. Functionally homologous non-peptide groups were substituted for the amino acids of the GSK-3 creating a hybrid peptide-non-peptide and non-peptide compounds capable of binding to Akt. The non-peptide compounds show increased stability and rigidity compared to peptide counterparts and are less susceptible to degradation. The bound non-peptide compounds exhibit an inhibitory effect on Akt, similar to peptide-based Akt inhibitors. | 01-14-2010 |
| 20090318684 | ROCK INHIBITORS AND USES THEREOF - The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are compounds that inhibit Rho-protein associated kinase function. Compounds of the invention include piperazinyl pyridines, piperazinylmethyl pyridines, piperazinyl ureas and carbamates, piperazinyl pyridines and quinoilines (including isoquinliones) as well as piperazinyl (including piperazinylmethyl) pyridines and quinolines (including isoquinolines). Compounds of the invention disrupt Rho-kinase activation and function and significantly inhibit tumor cell growth and induce tumor cell death. | 12-24-2009 |
| 20090318367 | Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs - The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are peptidomimetics that inhibit STAT function. Peptidomimetics of the invention display selective inhibition of specific STAT isoform homo-dimerization. The peptidomimetic probes of STAT1 function, described herein, provide the means to preferentially inhibit STAT1 over STAT3 through the exploration of the C-terminus. | 12-24-2009 |
| 20090316158 | Interferometric Chemical Sensor Array - The device is a gas/vapor/aerosol/particulate sensor with a receiver/transmitter option. This optical MEMS device is designed to be a self-contained optical bench, integrating of an entire interferometer into a MOEMS ‘optical bench’ system-on-a-chip, and includes multiplexed optical path sensors. The sensing structures consist of laser sources, semiconductor photo detectors, refractive/reflective optical elements, and specialized optical transmission paths. Each individual laser source and photodiode is an optical path sensor with a particular ‘functionalization.’ These sensing arm functionalizations are sensitive to unique chemical signatures and as a result can recognize and report various chemical agents present in the ambient environment. | 12-24-2009 |
| 20090305383 | Early Detection of Pathogens in Blood - The present invention is a method of extracting infectious pathogens from a volume of blood including the steps of creating a fibrin aggregate confining the pathogens and introducing a fibrin lysis reagent to expose the pathogens for analysis. The fibrin lysis reagent is preferably composed of plasminogen and streptokinase frozen in coincident relation until the fibrin lysis reagent is needed whereby streptokinase enzymatically reacts with plasminogen to form plasmin upon thawing. The plasminogen is suspended in an aqueous salt solution prior to freezing including NaCl and Na | 12-10-2009 |
| 20090291452 | MICRO-RNA PROFILES ASSOCIATED WITH ENDOMETRIAL CANCER DEVELOPMENT AND RESPONSE TO CISPLATIN AND DOXORUBICIN CHEMOTHERAPY - A method predicting of cancer chemoresponse of the population of cancer cells to the one or more chemotherapeutic agents. Our ability to treat patients with advanced stage and recurrent endometrial cancer is hampered by an incomplete understanding of the molecular basis of disease development and response to therapy. A novel class of gene products called microRNA (miRNA) has recently been implicated in the etiology of several different human cancers. Altered levels of expression of specific miRNAs may contribute to cancer development in a variety of cancers such as endometrial cancer and may also influence response to cytotoxic chemotherapy or other cancer treatments. Evidence is provided that differential expression of miRNAs contributes to endometrial carcinogenesis and further associates with sensitivity of endometrial cancer cells to various chemotherapeutic agents including cisplatin and doxorubicin chemotherapy. MiRNA profiles and their gene targets show promise as biomarkers of endometrial cancer chemo-response, and as a novel class of therapeutic targets for patients with endometrial cancer. | 11-26-2009 |
| 20090285884 | Platinum Complexes and Methods of Use - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro. | 11-19-2009 |
| 20090263958 | CLATHRATE COMPOUNDS AND METHODS OF MANUFACTURING - The present invention comprises new materials, material structures, and processes of fabrication of such that may be used in technologies involving the conversion of light to electricity and/or heat to electricity, and in optoelectronics technologies. The present invention provide for the fabrication of a clathrate compound comprising a type II clathrate lattice with atoms of silicon and germanium as a main framework forming lattice spacings within the framework, wherein the clathrate lattice follows the general formula Si | 10-22-2009 |
| 20090258927 | Method for the Modulation of Function of Transcription Factors - There is provided a method of modulating the function of transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding sites for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of transcription factors and a pharmaceutically acceptable carrier is also provided. Also provided is a treatment of patients having illnesses in which the activation of transcription factors play a role by administering to a patient an effective amount of an oligonucleotide which competitively binds the related transcription factor. | 10-15-2009 |
| 20090232824 | BIVM (BASIC, IMMUNOGLOBULIN-LIKE VARIABLE MOTIF-CONTAINING) GENE, TRANSCRIPTIONAL PRODUCTS, AND USES THEREOF - The subject invention provides polynucleotide sequences, designated BIVM, and transcriptional/translational products obtained from the polynucleotide sequences of the invention. The subject invention also provides polynucleotide and polypeptide sequences provided by SEQ ID NOs: 1-28. Also provided are methods of detecting the presence of BIVM nucleic acids or polypeptides in samples suspected of containing BIVM genes, BIVM transcriptional products, or BIVM translational products. These methods are also useful for the detection of BIVM orthologs. Other embodiments provide polypeptide and/or nucleic acid vaccines for the induction of an immune response to in an individual. Kits for detecting the presence of BIVM genes, orthologs thereof, BIVM polypeptides, or BIVM transcriptional products are also provided. | 09-17-2009 |
| 20090215792 | METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA CELLS - Here, the inventors disclose the treatment of imatinib mesylate resistant chronic myelogenous leukemia cells with a cotreatment of vorinostat (SAHA, suberoylanilide hydroxamic acid) and dasatinib, a dual Abl/Src kinase (TK) inhibitor. Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent alone, as well as synergistically induced loss of clonogenic survival, which was associated with greater depletion of Bcr-Abl, p-CrkL and p-STAT5 levels. Co-treatment with dasatinib and vorinostat also attenuated the levels of Bcr-AblE255K and Bcr-AblT315I and induced apoptosis of BaF3 cells with ectopic expression of the mutant forms of Bcr-Abl. Finally, co-treatment of the primary CML cells with vorinostat and dasatinib induced more loss of cell viability and depleted Bcr-Abl or Bcr-AblT315I, p-STAT5 and p-CrkL levels than either agent alone. | 08-27-2009 |
| 20090202586 | ATTENUATED VACCINE FOR TULAREMIA | 08-13-2009 |
| 20090192215 | Cytotoxin Compounds and Methods of Isolation - The present invention concerns groups of compounds derived from tunicates of the | 07-30-2009 |
| 20090170196 | CANCER TREATMENT USING C-TYPE NATRIURETIC PEPTIDE - The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention. | 07-02-2009 |
| 20090156654 | DERIVATIVE N-THIOLATED 2-OXAZOLIDINONE ANTIBIOTICS - This invention describes the discovery and synthesis of N-thiolated 2-oxazolidinones as a new class of anti bacterial agents. These compounds can be synthesized from 2-oxazolidinones by Ndeprotection and N-sulfenylation. These new substances were found to exhibit potent anti-bacterial activity, including bacteriostatic properties against | 06-18-2009 |
| 20090143596 | Supramolecular Assemblies and Building Blocks - The present invention generally relates to supramolecular assemblies and their modes of synthesis. The supramolecular assemblies include a 1:8 ratio of a supermolecular polyhedral building block and a triangular molecular building block, the supermolecular polyhedral building block having points of extension corresponding to the vertices of a rhombicuboctahedron for linking the supermolecular polyhedral building block to the triangular building block. | 06-04-2009 |
| 20090137018 | MAGNETIC THREE-DIMENSIONAL CELL CULTURE APPARATUS AND METHOD - A culture apparatus and method for growing cells and tissue in a three-dimensional configuration harnesses magnetic, paramagnetic, ferromagnetic and diamagnetic forces. The cells or tissue are grown with magnetized core particles and are suspended via magnetic forces in a native, non-restricted, three-dimensional configuration while being maintained in a normal gravity (1 g) growth environment in the absence of rotational alteration of the gravity vector. | 05-28-2009 |
| 20090131994 | Passive Electric Field Focus System for In Vivo and In Vitro Applications - The present invention provides a system and method of directing, focusing, or concentrating electrical charges within a defined electric field so that these charges can be used to exert forces on cells and tissues in vivo and/or cell cultures in vitro. The present invention reduces and/or eliminates the damage at a target site that would normally be caused by an electrode that acts as a current source or sink to accomplish the same task. | 05-21-2009 |
| 20090075932 | METHOD OF SELECTIVELY INHIBITING PKCiota - PKCiota inhibitor 1H-imidazole-4-carboxamide, 5-amino-1-[2,3-dihydroxy-4-[(phosphonooxy)methyl]cyclopentyl]-,[1R-(1α,2β,3β,4α)], (ICA-1), targets a unique sequence (amino acid residues 469-475) in the catalytic domain of PKCiota and inhibits PKCiota activity. The data shows suprising and unexpected ability of ICA-1 to selectively inhibit the proliferation of cells that overexpress PKCiota. | 03-19-2009 |
| 20090069420 | Small molecule inhibitors of STAT3 with anti-tumor activity - The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S3I-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis. The invention further includes an in-vitro screening test for the presence of malignant cells in a mammalian tissue; a method of identifying inhibitors of constitutive Stat3 activation, Stat3-DNA binding, Stat5-DNA binding, and/or Stat3 dimerization; and a method of identifying anti-cancer agents. | 03-12-2009 |
| 20090062206 | Urodilatin Cancer Treatment - Urodilatin, a peptide formed in the kidney, has significant anticancer effects eliminating two-thirds of cancer cells within 24 hours. | 03-05-2009 |
| 20090054829 | Electrogenic pump molecule control - Activation of electrogenic pump molecules can be realized by a dynamic entrainment procedure which includes two steps: synchronization of individual pump molecules to work at the same pumping pace, and gradual modulation of the synchronization frequency. We studied synchronization of the Na/K pump molecules in a physiological running mode by applying the concept of an electronic synchrotron to the biological system. Both theoretical analysis and experimental results showed that individual Na/K pump molecules can be synchronized by a well designed oscillating electric field. The synchronized pump currents show separated inward and outward pump currents and a magnitude ratio of 3:2 reflecting stoichiometric number of the pump molecules. | 02-26-2009 |
| 20090028855 | INHIBITORS OF AKT/PKB WITH ANTI-TUMOR ACTIVITY - The subject invention concerns materials and methods for inhibiting the Akt/PKB pathway. In one embodiment, a compound of the invention inhibits kinase activity and/or phosphorylation levels of Akt proteins. The subject invention also concerns methods for inhibiting or killing a cancer cell or other cell in which expression of an Akt protein is elevated or constitutively active, comprising contacting the cell with an effective amount of a compound of formula I. The subject invention also concerns methods for treating cancer or a tumor in a person or animal comprising administering all effective amount of a compound of formula I to the person or animal. | 01-29-2009 |
| 20090017012 | METHODS OF DIAGNOSING AND TREATING CANCER - The invention relates to methods of determining an appropriate cancer therapy for a subject based on intratumoral expression levels of Ribonucleotide Reductase M1 (RRM1) and thymidylate synthase (TS) gene expression, as well as to methods of predicting clinical outcome (prognosis) based on cytoplasmic levels of TS protein. Compositions and kits useful for the methods are also provided. | 01-15-2009 |
| 20090016998 | NOVEL METHOD OF PRENATAL ADMINISTRATION OF MAMMALIAN UMBILICAL CORD STEM CELLS FOR THE INTRAUTERINE TREATMENT OF MAMMALIAN LYSOSOMAL STORAGE DISEASES - A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease. | 01-15-2009 |
| 20090016995 | Method of Treating Cognitive Decline and Synaptic Loss Related to Alzheimer's Disease - A method treating a subject with Alzheimer's disease wherein Aβ-reactive immune cells, splenocytes and lymphocytes, are generated in vitro or in vivo, re-stimulated in vitro, and then adoptively transferred into the cognitively-impaired subject. The population of immune cells can be derived from a donor with a natural or adaptive immune response to Aβ, stimulated by exposure to Aβ in vivo. The donor cells are then collected and re-stimulated by subsequent exposure to Aβ in vitro prior to administration to the subject. Alternatively, the population of immune cells can be derived from the subject and then stimulated by exposure to Aβ in vitro. | 01-15-2009 |
| 20090016866 | Manual Wheelchair Loader - A manual wheelchair loader design to lift and place an article, such as a collapsible wheelchair, into the cargo area of a vehicle. The loader includes a base adapted to rest on a substantially flat surface within the vehicle. At least one support arm is connected to the base to hold a carriage. The carriage is adapted to rotate between a first position and a second position. The carriage further has a lower support surface adapted to support the article being loaded when the frame is in a first position. The carriage also has a lateral support surface adapted to support the article being loaded when the carriage is in a second position. A ramp is hingedly connected to lower support surface for wheeling the article thereto. | 01-15-2009 |
| 20090013609 | Polymeric Microgels for Chemical Mechanical Planarization (CMP) Processing - Organic-inorganic composites were prepared as colloidal particles of a cross-linked, thermally responsive polymer. Hybrid PNIPAM-polysiloxane particles and composite polymeric particles with embedded nanoparticles of an inorganic metal-oxide (MO | 01-15-2009 |
| 20090004717 | Device and Method to Facilitate Directed Delivery and Electroporation Using a Charged Stream - A method for facilitating a delivery of a molecule into an interior space of a cell includes the steps of introducing a molecule into a biological structure comprising a cell and applying a substantially continuous low-level electric field, in the form of non-thermal plasma (ionized gas) generated by a direct current voltage applied to an electrode, to the molecule and biological structure. The field is applied for a duration sufficient to effect a change in porosity the cell of the biological structure sufficient to facilitate an entry of a desired molecule into an interior thereof. | 01-01-2009 |
| 20090000850 | HANDS-FREE POWERED MOBILITY DEVICE - An electrically operable wheelchair having a seat, a base with a pair of motors respectively coupled with the main support wheels, a position detection assembly, and a controller coupled with the position detection assembly and the motors for controlling wheelchair operation in order to effect desired wheelchair movements. The hands-free input device of the invention, which includes the position detection assembly and a position detection device, provides input signals representative of desired wheelchair movements to the controller. The position detection device detects the position of the seat. Movement of the seat, rather than a joystick, creates the voltage signals which are then transmitted to the wheelchair controller. | 01-01-2009 |
| 20080319724 | ELECTRIC POWER DISTRIBUTION INTERRUPTION RISK ASSESSMENT CALCULATOR - Based on common weather conditions, novel methods are disclosed for the prediction of electrical power distribution interruptions and for interruption risk assessment based on immediate weather conditions. Daily, hourly, and bi-hourly weather data are used to predict the number of interruptions and to normalize reliability indices for weather. | 12-25-2008 |
| 20080319068 | Novel Polymorph of Acetylsalicylic Acid, and Methods of Making and Using the Same - A polymer of aspirin is provided by the present invention. Methods of making and using the same are also provided. | 12-25-2008 |
| 20080289483 | METHOD OF MODIFYING THE FREQUENCY RESPONSE OF A WOODEN ARTICLE - Disclosed is a method for modifying the frequency response of a wooden article by exciting the article with acoustic energy. Frequency response is the measure of a system's spectrum response at the output due to a signal of varying frequency (but constant amplitude) at its input. The acoustic energy includes at least one excitation frequency, a composite broadband frequency component, or a combination thereof, which is preferably in the audible spectrum (20 to 20,000 Hz). The use of acoustic energy from the remote source provides non-contact excitation of the wooden article. In one embodiment, the acoustic energy is at least one sound wave which comprises at least one resonant frequency of the wooden article, at least one acoustic mode of the wooden article, at least one discrete frequency, a broadband frequency component, or any combination thereof. | 11-27-2008 |
| 20080280812 | HUMAN IMMUNOSUPPRESSIVE PROTEIN - A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells. T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G.sub.0/G.sub.1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose, HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells. | 11-13-2008 |
| 20080279835 | Method of Stem Cell Therapy for Cardiovascular Repair - A method of treating acute myocardial infarction has the steps of providing human umbilical cord blood cells (HUCBC); and administering the HUCBC to the individual with the acute myocardial infarction at particular time intervals after said myocardial infarction. Preferably the intervals are about one to about three hours or about 12 to about 48 hours after the acute myocardial infarction. | 11-13-2008 |
| 20080273775 | CARTESIAN HUMAN MORPHO-INFORMATIC SYSTEM - The present invention is a three dimensional Cartesian coordinate system for the human body, having three perpendicular and intersecting planes. The present invention is based upon the use of the three cardinal planes, in the universally recognized orientations. The cardinal planes in accordance with the present invention are: Sagittal: midsagittal plane, Transverse: upper-most extent of the iliac crests, and Coronal: anterior-most aspect of the vertebral canal. The point at which these planes intersect defines the 0,0,0 location in the human body. | 11-06-2008 |
| 20080250983 | Folding Armrest Tray for Wheelchairs - A table assembly mounted on a wheelchair using a friction hinge. A housing containing the table is mounted along the side of the chair arm. The table assembly has a table surface moveable between two in-use positions, the first position extends across the front of the chair and the other extends laterally to the side of the chair. The table surface may be stowed in the housing alongside the chair, inside the brake and the drive wheel or beneath the arm. The assembly is releasably connected to the chair so it is readily removed and replaced. | 10-16-2008 |
| 20080234946 | PREDICTIVE RADIOSENSITIVITY NETWORK MODEL - This invention is a model that simulates the complexity of biological signaling in a cell in response to radiation therapy. Using gene expression profiles and radiation survival assays in an algorithm, a systems model was generated of the radiosensitivity network. The network consists of ten highly interconnected genetic hubs with significant signal redundancy. The model was validated with in vitro tests perturbing network components, correctly predicting radiation sensitivity 2/3 times. The model's clinical relevance was shown by linking clinical radiosensitivity targets to the model network. Clinical applications were confirmed by testing model predictions against clinical response to preoperative radiochemotherapy in patients with rectal or esophageal cancer. | 09-25-2008 |
| 20080234401 | METHOD OF PRODUCING INTERCONNECTED VOLUMETRIC POROSITY IN MATERIALS - A method to create interconnected porosity in materials that can be poured or injected into a cast. The process allows the arrangement of interconnected volumetric porosity to be directed in materials that are poured or injected into a cast. This process allows a manufacturer to tailor porosity with any size, shape, and configuration with the dissolvable material used to create the pores. This procedure can be applied to medical materials to direct bone growth or implant attachment. These resulting porous materials can include, but is not limited to short fiber reinforced epoxy or epoxy. | 09-25-2008 |
| 20080226836 | CLATHRATE COMPOUNDS AND METHOD OF MANUFACTURING - The present invention comprises new materials, material structures, and processes of fabrication of such that may be used in technologies involving the conversion of light to electricity and/or heat to electricity, and in optoelectronics technologies. The present invention provide for the fabrication of a clathrate compound comprising a type II clathrate lattice with atoms of silicon and germanium as a main framework forming lattice spacings within the framework, wherein the clathrate lattice follows the general formula Si | 09-18-2008 |
| 20080218925 | MOV FAILURE MODE IDENTIFICATION - A surge protector includes a thermal fuse, a metal oxide varistor electrically connected in series relation to the thermal fuse, and a detection network electrically connected in parallel relation to the thermal fuse and the metal oxide varistor. A first indicating means indicates whether or not the thermal fuse is in operation and a second indicating means indicates whether or not the metal oxide varistor is in operation. | 09-11-2008 |
| 20080214494 | METHOD OF DRUG DELIVERY BY CARBON NANOTUBE-CHITOSAN NANOCOMPLEXES - Functionalized Single Wall Carbon Nanotube (SWCNT) complexed with nanochitosan for use in the delivery of bioaffecting substances and diagnostic applications. fSWCNT complexed with the chitosan NG042 were used for delivery of DNA-encoding EGFP reporter protein and peptide. The results demonstrate that shown CNT-chitosan hybrid nanoparticles exhibit significantly higher transfection efficiency in vivo than chitosan alone. Furthermore, the functionalized nanotubes were tested for peptide transfer into HEK293 cells. The results showed that the hybrid nanoparticles efficiently transferred peptides. Together, these results show that hybrid SWCNT-chitosan particles increase DNA and peptide transfer into cells. | 09-04-2008 |
| 20080206829 | EPOXY ENHANCED POLYMER MEMBRANE TO INCREASE DURABILITY OF BIOSENSORS - The present invention provides a polymer membrane enhanced with cured epoxy resin for use as the outer membrane of biosensors. The membrane includes approximately 30-80% epoxy resin adhesives, 10-60% polymer such as poly(vinyl chloride), polycarbonate and polyurethane and 0-30% plasticizers and 5-15% surface modifier reagent such as polyethylene oxide-containing block copolymers. Utilizing the polymer membrane of the present invention, a three-layered sensing element has been developed. This sensing element will be particularly useful for miniaturized biosensors used for in vitro blood measurements or for continuous in vivo monitoring such as implantable biosensors. This element includes an enzyme layer, an interference-eliminating layer and the novel polymer member of the present invention as the outer polymer layer. This novel sensing element shows excellent response characteristics in solutions and has an extremely long lifetime. This technology is particularly useful for improving the lifetime of implantable biosensors. | 08-28-2008 |
| 20080206206 | BONE MARROW-DERIVED NEURONAL CELLS - Bone marrow stromal cells (BMSC) differentiate into neuron-like phenotypes in vitro and in vivo, engrafted into normal or denervated rat striatum. The BMSC administered into the ventricle did not remain localized to the site of the graft, but migrated throughout the brain and integrated into specific brain regions in various architectonic patterns. The most orderly integration of BMSC was in the laminar distribution of cerebellar Purkinje cells, where the BMSC-derived cells took on the Purkinje phenotype. The BMSC exhibited site-dependent differentiation and expressed several neuronal markers including neuron-specific nuclear protein, tyrosine hydroxylase and calbindin. Treated BMSC implanted intrastriatally stayed in the cortex and the striatum, produced tyrosine hydroxylase which produces the dopamine needed in Parkinson's disease. | 08-28-2008 |
| 20080200379 | Diagnostic markers of human female infertility - The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf. | 08-21-2008 |
